To ask the Secretary of State for Health, what estimate he has made of the (a) reduction in cases of and deaths from human pappillomavirus (HPV) as a result of the introduction of the HPV vaccine to the UK schedule in 2008, (b) number of HPV vaccinations administered in each year since that programme began and (c) cost of delivering that programme in each year since 2008.
HPV vaccination will eventually prevent hundreds of deaths due to cervical cancer every year. Public Health England (PHE) expect the major benefit of the vaccination programme, i.e. a decrease in cervical cancer, which peaks in women between 25 and 50; will be seen in some years’ time.
Table 1: Number of HPV vaccine doses given for the academic years 2008/09 to 2013/14.
Total doses given
2008/09 -2010/111 (routine and catch-up cohorts*)
2011/122 (routine only)
2012/133 (routine only)
2013/144 (routine only)
2014/15 (routine only)
*Routine cohort are school Yr8 females (aged 12-13 years) in academic years 2008/09, 2009/10, 2010/11) and catch-up cohorts are females born between 1/9/1990 and 31/8/1995. $ Data for 2008/09, 2009/10 and 2010/11 are combined as these years had both routine and catch-up cohorts targeted and include some ‘mop-up’ vaccinations for eligible females receiving vaccine(s) after the academic year they first became eligible for vaccination.
Table 2. The cost of delivering the HPV programme since 2008.
Estimated total programme costs
£114 million (includes catch up campaign)
£27 million (change in dosage schedule)
£16.3 million (change from 3 to 2 doses)
These are the estimated full programme costs (including the cost of the vaccine) for England, inclusive of VAT.